biosimilar limited use in some health systems for biosimilars are not well understood by many health professionals and patients. This knowledge gap is exacerbated by
Objective: To summarize and review the clinical data from the Food and Drug Administration (FDA) biosimilars approved for use in the treatment of cancer and
Objective: This study aimed to analyze the cost-effectiveness and biosimilar infliximab compared with conventional therapy in fireproof moderate to severe Crohn’s disease (CD) in Thailand.Materials
Objective: There are no extensive study to compare the effectiveness between the originator rituximab (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis
Last year, more than 46 unique biosimilars have been approved by the EMA and / or US-FDA following patent expiry of the reference product. Biosimilars